Heterogeneity of Estimated GFR Slopes According to Etiology, Estimated GFR and Urinary Albumin-to-Creatinine Ratio in a Large Cohort of Patients With CKD

Figures

• 

  Figure 1. Forest plot of model coefficients that affect the intercept (baseline estimated glomerular filtration rate) and the estimated glomerular filtration rate slope. In model 2, the reference category includes male sex, UACR < 30 mg/g and as disease etiology hypertensive kidney disease. Panel A shows the main effects of the model whereas panel B shows the interaction effects with time. The model intercept (β0=87.33, 95% confidence interval [84.39–90.27]) is not shown. See Supplementary Table S3 for further model details. Positive effects are marked with blue, negative with red. ADPKD, autosomal dominant polycystic kidney disease; UACR, urinary albumin-to-creatinine ratio.

• 

  Figure 2. Modelled individual and mean eGFR slopes by disease etiology, age, and sex over 6.5 years follow-up. Modelled eGFR values as derived from model 3 for all participants after 6.5 years of follow-up by disease etiology, sex, and age group. Age subgroups are separated at the median age of 63 years. Upper panels (a–e): modelled eGFR slope for each participant (thin grey lines in the background) within the different disease etiology subgroups. Thick lines represent mean slopes within each disease etiology for age (solid line: < 63 years vs. dotted lines ≥ 63 years) and for sex (male: blue, red: female). Modelled eGFR values < 0 are treated as missing. Lower panels (f–j): Lines show individual examples of modelled eGFR slopes with the observed values (dots) for each participant within the different disease etiology subgroups. ADPKD, autosomal dominant polycystic kidney disease, eGFR: estimated glomerular filtration rate; f, female; m, male.

• 

  Figure 3. eGFR slope according to baseline eGFR categories in each disease etiology group. Mean eGFR slope rates in ml/min per 1.73 m2/yr for each disease etiology group (y-axis) and for different chronic kidney disease stages at baseline (x-axis) for > 20 participants (using model 2). According to the Kidney Disease: Improving Global Outcomes guidelines: CKD stage G1, ≥ 90 ml/min per 1.73 m2; stage G2, 60–89 ml/min per 1.73 m2; stage G3a, 45–59 ml/min per 1.73 m2; stage G3b, 30–44 ml/min per 1.73 m2; stage G4, 15–29 ml/min per 1.73 m2; and stage G5, < 15 ml/min per 1.73 m2 without kidney replacement therapy. ADPKD, autosomal dominant polycystic kidney disease; eGFR, estimated glomerular filtration rate.

• 

  Figure 4. Modelled eGFR slope according to eGFR and albuminuria categories at baseline. Mean modeled eGFR slope in ml/min per 1.73 m2/yr for each eGFR (y-axis) and albuminuria (x-axis) category at baseline for > 30 participants (using model 2). The mean slope by albuminuria was A1: −0.66, A2: −1.29, A3: −2.75. According to Kidney Disease: Improving Global Outcomes guideline: CKD stage G1 ≥ 90 ml/min per 1.73 m2, stage G2 60–89 ml/min per 1.73 m2, stage G3a 45–59 ml/min per 1.73 m2, stage G3b 30–44 ml/min per 1.73 m2, stage G4 15–29 ml/min per 1.73 m2, and stage G5 < 15 ml/min per 1.73 m2 without kidney replacement therapy. Albuminuria expressed as urine albumin creatinine ratio in mg/g according to Kidney Disease: Improving Global Outcomes categories. eGFR, estimated glomerular filtration rate.